This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.
Solid Tumor, Adult
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
-
Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
Yale Cancer Center, New Haven, Connecticut, United States, 06519
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States, 87106
Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York, United States, 10032
Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065
University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19106
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States, 19107
MD Anderson Cancer Center, Houston, Texas, United States, 77030
The START Center for Cancer Care, San Antonio, Texas, United States, 78229
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Linnaeus Therapeutics, Inc.,
Tina Garyantes, PhD, STUDY_DIRECTOR, Linnaeus Therapeutics, Inc.
2024-12-15